The medical imaging industry is undergoing a major transformation as AI-driven solutions redefine how clinicians assess the human heart. The medical image management sector is projected to reach $9.06 billion by 2032, signaling a shift away from traditional, expensive imaging equipment toward software-based diagnostic tools. Point-of-care technologies are also expanding rapidly, with the market expected to reach $70.92 billion. Hospitals are increasingly moving from fixed MRI suites to portable, bedside AI-powered devices that provide hospital-grade precision. This change has created significant opportunities for companies building the digital infrastructure to support these new care models, including VentriPoint Diagnostics, Butterfly Network, Hyperfine, Hologic, and GE HealthCare.
Health Technology Insights: Adagio Medical Adds Executives to Boost ULTC Launch
A key driver of this shift is the change in federal reimbursement policies. The Centers for Medicare and Medicaid Services is launching the ACCESS Model in July 2026, which prioritizes measurable patient outcomes over test volume. This change reinforces the value of software-defined imaging platforms, allowing providers to reduce operational costs while using AI to detect cardiac conditions before they become urgent.
Ventripoint Diagnostics is leading in this space with subscription-based solutions that convert standard 2D ultrasound scans into 3D volumetric heart models with MRI-level accuracy. Strong investor interest recently led the company to double its private placement from $500,000 to $1 million. The funds will support commercialization, manufacturing expansion, regulatory filings, and operational needs.
The focus is shifting from clinical capability to demonstrable economic value. Ventripoint partnered with Summit Sciences to develop advanced ROI models that quantify cost savings and efficiency gains for hospitals. These models use real-world data to show how hospitals can reduce costs, improve diagnostic accuracy, and optimize resource allocation. Hugh MacNaught, President and CEO of Ventripoint Diagnostics, stated that the partnership with Summit Sciences allows the company to present stronger value propositions to healthcare providers and demonstrates their commitment to advancing cardiac care while delivering measurable economic benefits. Dana Friesen, CEO of Summit Sciences, brings over 15 years of experience in financial analysis and ROI optimization in medical technology and has worked extensively with indigenous health networks, aligning with Ventripoint’s outreach to underserved communities.
Health Technology Insights: Connecticut HIE Adopts PIQXL Gateway to Boost Data Quality
Ventripoint also partnered with the Nisg̱a’a Valley Health Authority to create a model for delivering advanced cardiac imaging to remote and Indigenous populations. The hub-and-spoke system enables local providers to capture ultrasound scans and transmit them digitally to specialists for rapid interpretation. The company also announced David Swetlow as its new Chief Financial Officer. Swetlow has more than 15 years of experience leading high-growth medical technology companies and will help drive Ventripoint’s commercial expansion. The firm’s Device-as-a-Service subscription approach is expected to shorten sales cycles and make advanced cardiac imaging accessible to a broader range of healthcare facilities without large upfront costs.
In parallel, Hologic announced that its Genius AI Detection technology successfully identified nearly one-third of previously missed breast cancer cases in a retrospective analysis of 7,500 digital breast tomosynthesis exams at Massachusetts General Hospital. Mark Horvath, President of Breast and Skeletal Health Solutions at Hologic, highlighted that the study demonstrates AI’s ability to detect cancers that might otherwise go unnoticed and provides guidance for future product development. The technology flagged almost 90 percent of 500 breast cancer cases already identified by radiologists, particularly invasive ductal carcinomas and cancers with positive lymph nodes.
GE HealthCare and Mayo Clinic unveiled GEMINI-RT, a new collaboration aimed at personalizing radiation therapy by combining imaging, AI, and patient monitoring. Bryan Traughber, M.D., vice chair of innovation for radiation oncology at Mayo Clinic, explained that the initiative allows clinicians to model individual patient journeys and deliver truly personalized radiation treatments. GEMINI-RT focuses on automating repetitive tasks, supporting predictive oncology, integrating multi-modal therapies, and providing continuous patient monitoring using AI and biomarkers. The research will be based at Mayo Clinic’s Rochester campus and targets improved outcomes for over 2 million U.S. cancer patients annually.
Health Technology Insights: ACCO Brands to Acquire EPOS
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
